Centessa Pharmaceuticals plc ADR [CNTA] stock is trading at $24.9, up 2.34%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CNTA shares have gain 3.11% over the last week, with a monthly amount glided 8.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] stock has seen the most recent analyst activity on October 28, 2025, when Stephens initiated its Overweight rating and assigned the stock a price target of $35. Previously, Wells Fargo started tracking the stock with Overweight rating on September 03, 2025, and set its price target to $31. Truist started tracking the stock assigning a Buy rating and suggested a price target of $30 on July 21, 2025. Needham initiated its recommendation with a Buy and recommended $35 as its price target on May 28, 2025. Chardan Capital Markets started tracking with a Buy rating for this stock on May 08, 2025, and assigned it a price target of $30. In a note dated March 31, 2025, Piper Sandler initiated an Overweight rating and provided a target price of $38 on this stock.
Centessa Pharmaceuticals plc ADR [CNTA] stock has fluctuated between $9.60 and $25.31 over the past year. Currently, Wall Street analysts expect the stock to reach $25.5 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $24.9 at the most recent close of the market. An investor can expect a potential return of 2.41% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -12.94%, Pretax Profit Margin comes in at -14.2%, and Net Profit Margin reading is -14.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.56 and Total Capital is -0.45. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.20 points at the first support level, and at 23.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.37, and for the 2nd resistance point, it is at 25.83.
Ratios To Look Out For
For context, Centessa Pharmaceuticals plc ADR’s Current Ratio is 10.12. In addition, the Quick Ratio stands at 10.12 and the Cash Ratio stands at 1.49. Considering the valuation of this stock, the price to sales ratio is 221.40, the price to book ratio is 9.67.
Transactions by insiders
Recent insider trading involved Accardi Mario Alberto, President, Orexin Program, that happened on Oct 27 ’25 when 8000.0 shares were sold. Officer, Accardi Mario Alberto completed a deal on Oct 27 ’25 to buy 8000.0 shares. Meanwhile, General Counsel HUSSAIN IQBAL J sold 6000.0 shares on Oct 15 ’25.
